Filing Flows › Twist Bioscience (TWST) › Q4 FY24
Twist Bioscience (TWST) Q4 FY24 earnings results (fourth quarter fiscal 2024)
10-K filed Nov 18, 2024
Twist Bioscience (TWST) reported revenue of $84.7M for the fourth quarter fiscal 2024 (Q4 FY24), +27% from a year earlier and +4% from the quarter before. Operating margin was -42.5%, net loss $34.7M (40.9% of revenue).
Twist Bioscience, Q4 FY24: revenue $84.7M (+26% year over year), operating margin -42.5%, net loss $34.7M, operating cash flow −$15.3M. The chart follows the revenue to costs, profit and cash.
| Q4 FY24 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $84.7M | +4% | +27% |
| Operating profit | −$36.0M | — | — |
| Net earnings | −$34.7M | — | — |
| Operating cash flow | −$15.3M | — | — |
What changed
Revenue was $84.7M in Q4 FY24, up 27% year over year and up 4% from the previous quarter. NGS tools was the largest line at 54% of revenue.
Operating costs exceeded revenue by $36.0M, an operating margin of -42.5%. Total costs grew 3% against revenue growth of 27%. The fastest-growing cost line was SG&A (+12%). The quarter ended with a net loss of $34.7M, narrower than the previous quarter's $85.6M loss.
Operating cash flow was −$15.3M. Non-cash charges added back $6.7M of depreciation and amortization and $12.3M of share-based compensation. Capital expenditures of $2.0M exceeded it, leaving free cash flow of −$17.3M.
Questions
What was Twist Bioscience's revenue in the fourth quarter fiscal 2024?
Twist Bioscience (TWST) reported revenue of $84.7M for the fourth quarter fiscal 2024 (Q4 FY24), +27% from a year earlier and +4% from the quarter before.
Was Twist Bioscience profitable in the fourth quarter fiscal 2024?
Operating loss was $36.0M (-42.5% of revenue) and net loss $34.7M.
Source: Twist Bioscience 10-K on SEC EDGAR.